As of close of business last night, Phathom Pharmaceuticals Inc’s stock clocked out at $10.14, down -3.15% from its previous closing price of $10.47. On the day, 949391 shares were traded.
Ratios:
To gain a deeper understanding of PHAT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.22 and its Current Ratio is at 10.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on January 05, 2024, Reiterated its Buy rating but revised its target price to $26 from $23 previously.
On August 09, 2023, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $28.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 08 ’24 when Henderson Molly sold 3,435 shares for $11.10 per share. The transaction valued at 38,128 led to the insider holds 95,263 shares of the business.
Curran Terrie sold 16,851 shares of PHAT for $153,513 on Mar 22 ’24. The President and Chief Executive now owns 410,784 shares after completing the transaction at $9.11 per share. On Jan 24 ’24, another insider, TAKEDA PHARMACEUTICAL CO LTD, who serves as the 10% Owner of the company, sold 3,703,703 shares for $8.10 each. As a result, the insider received 29,999,994 and left with 3,755,583 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 872.04.
Stock Price History:
Over the past 52 weeks, PHAT has reached a high of $17.02, while it has fallen to a 52-week low of $6.07.
Shares Statistics:
A total of 57.97M shares are outstanding, with a floating share count of 27.69M. Insiders hold about 53.27% of the company’s shares, while institutions hold 44.57% stake in the company.
Earnings Estimates
As of right now, Phathom Pharmaceuticals, Inc. analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $24.55, with high estimates of $10.53 and low estimates of $34.45.
EPS for the following year is $Stocks, with Stocks analysts recommending between $Stocks and $ETF.
